AbbVie presents ESMO data: October 30 results test AbbVie stock

Published on 10/20/2026 at 11:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie presented seven ESMO assets on October 18, 2026. AbbVie stock costs EUR 253.00 on October 20, 2026, 0.08 percent above the Xetra close.

Pipeline data and earnings date

AbbVie outlined seven oncology assets for the ESMO Congress on October 18, 2026.
Second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year.
AbbVie stock trades at EUR 253.00 at 11:08 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.08 percent above the Xetra close of October 19, 2026.
AbbVie is scheduled to report third-quarter results on October 30, 2026.

Redaktionsfoto des NYSE-Handelssaals mit Händlern und grünen Pharma-Aktiencharts auf Monitoren — AbbVie Inc. US00287Y1091 NYSE Handelssaal Editorial Fotografie Händler Pharma Aktiencharts grüne Kurven auf Monitoren, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 253.00 at Lang & Schwarz on October 20, 2026, at 11:08 a.m. CEST, plus 0.08 percent versus the Xetra close of October 19, 2026 at EUR 252.80. The company had presented new and updated data from seven assets for the European Society for Medical Oncology Congress, while its third-quarter results are scheduled for October 30, 2026.

According to MarketScreener on October 19, AbbVie said on October 18 that its broad oncology portfolio would feature data across lung, colorectal, ovarian, prostate and gastric cancers. The congress is scheduled for October 23 through October 27 in Madrid, giving the pipeline update a defined near-term timetable.

ESMO expands the pipeline picture

The ESMO program adds clinical evidence to AbbVie's existing commercial base. The company also reported new ABBV-466 Crohn's disease data, with higher endoscopic remission rates than either single-pathway treatment, according to Yahoo Finance on October 19.

What will October 30 test?

AbbVie's second-quarter revenue was USD 16.99 billion, up 10.20 percent from the prior-year quarter, while diluted GAAP earnings per share were USD 2.03. MarketBeat reported that adjusted earnings per share reached USD 3.65 against a USD 3.61 consensus, while revenue exceeded the USD 16.80 billion estimate. The numbers give the October report a clear benchmark for newer medicines and the post-Humira transition.

Three dates frame the next step

AbbVie's recent chronology has three measurable milestones. On July 31, 2026, the company reported USD 16.99 billion in second-quarter revenue and adjusted earnings per share of USD 3.65, according to MarketBeat. On September 3, 2026, AbbVie closed its Apogee acquisition and reaffirmed adjusted third-quarter earnings guidance of USD 3.84 to USD 3.88, as reported by Drillr.ai. On October 18, 2026, the company announced the seven-asset ESMO program.

The next two dates are October 23, 2026, when the ESMO Congress begins, and October 30, 2026, when AbbVie is scheduled to report third-quarter results, according to MarketBeat.

Stock holds near the Xetra close

The small euro gain leaves the market response muted before the clinical data and earnings dates arrive. AbbVie stock was trading at EUR 253.00 at Lang & Schwarz on October 20, 2026, at 11:08 a.m. CEST, plus 0.08 percent versus the Xetra close of October 19, 2026 at EUR 252.80. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.